Article Contents ::
- 1 The Brand Name BOZENA Has Generic Salt :: BOSENTAN
- 2 BOZENA Is From Company Cipla Priced :: Rs. 1150
- 3 BOZENA have BOSENTAN is comes under Sub class Miscellaneous of Main Class Anti Infectives
- 4 Main Medicine Class:: Anti Infectives Sub Medicine Class :: Miscellaneous
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name BOZENA Has Generic Salt :: BOSENTAN
BOZENA Is From Company Cipla Priced :: Rs. 1150
BOZENA have BOSENTAN is comes under Sub class Miscellaneous of Main Class Anti Infectives
Main Medicine Class:: Anti Infectives Sub Medicine Class :: Miscellaneous
Salt Name : OR Generic Name | Form | Price : MRP /Probable | Packing | ||
BOSENTAN | TAB | Rs. 1150 | 10 |
Brand Name | Company / Manufacturers | Strength | Unit | Price / 10 |
BOZENA | Cipla | 62.5MG | 10 | Rs. 1150 |
Company Brand Name | Salt Combination | Main Medical Class | Sub Medical Class |
From Cipla :: BOZENA | BOSENTAN | Anti Infectives | Miscellaneous |
Indications for Drugs ::
Pulmonary Arterial Hypertension (PAH)
Drug Dose ::
Adult Dosage: Initiate treatment at 62.5 mg twice daily for 4 weeks and then increase to the maintenance dose of 125 mg twice daily. Doses above 125 mg twice daily did not appear to confer additional benefit sufficient to offset the increased risk of hepatotoxicity. Bosentan should be administered in the morning and evening with or without food.
Contraindication ::
Patients with WHO Class II symptoms showed reduction in the rate of clinical deterioration and a trend for improvement in walk distance. Physicians should consider whether these benefits are sufficient to offset the risk of hepatotoxicity in WHO Class II patients, which may preclude future use as their disease progresses.
Drug Precautions ::
Hepatotoxicity and teratogenicity. Elevations of AST or ALT associated with Bosentan are dose-dependent, occur both early and late in treatment, usually progress slowly, are typically asymptomatic, and usually have been reversible after treatment interruption or cessation. Aminotransferase elevations also may reverse spontaneously while continuing treatment with Tracleer. Liver aminotransferase levels must be measured prior to initiation of treatment and then monthly and therapy adjusted accordingly .Discontinue Bosentan if liver aminotransferase elevations are accompanied by clinical symptoms of hepatotoxicity (such as nausea, vomiting, fever, abdominal pain, jaundice, or unusual lethargy or fatigue) or increases in bilirubin > 2
Drug Side Effects ::
More common Blurred vision confusion dizziness dark urine faintness or lightheadedness when getting up from a lying or sitting position fever with or without chills light-colored stools loss of appetite nausea and vomiting stomach pain sudden sweating unusual tiredness or weakness yellow eyes or skin
Pregnancy category ::
5
Drug Mode of Action ::
Competitive antagonist of endothelin-1; blocks endothelin receptors on vascular endothelium and smooth muscle resulting in inhibition of vasoconstriction
Drug Interactions ::
Increased bosentan levels w/ CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, diltiazem), CYP2C9 inhibitors (e.g. amiodarone, fluconazole), tacrolimus. Rifampicin initially increases but subsequently decreases bosentan concentration. May decrease plasma levels of warfarin, statins (e.g. simvastatin, lovastatin), hormonal contraceptives, sildenafil, tadalafil. Potentially Fatal: Increased risk of hepatotoxicity may occur w/ glibenclamide. Ciclosporin markedly increases bosentan concentration.